High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study

H. D. Preisler, A. Raza, M. Barcos, N. Azarnia, R. Larson, G. Browman, I. Walker, H. Grunwald, P. D'Arrigo, A. Stein, M. Bloom, J. Goldberg, A. Gottlieb, J. Bennett, J. Kirshner, R. Priore

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Abstract

Fifteen patients with myelodysplastic/myeloproliferative disorders were treated with high‐dose cytosine arabinoside therapy. While severe toxicity was produced in every patient, only two of the 15 patients entered complete remission and two achieved partial remission status. The therapeutic responses were confined to patients who had severe myelofibrosis of apparently recent onset.

Original languageEnglish
Pages (from-to)131-134
Number of pages4
JournalAmerican Journal of Hematology
Volume23
Issue number2
DOIs
StatePublished - Oct 1986
Externally publishedYes

Keywords

  • high‐dose araC
  • preleukemia

Fingerprint

Dive into the research topics of 'High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study'. Together they form a unique fingerprint.

Cite this